Objective: The study objectives were to examine the association between menopause status and diabetes risk among women with glucose intolerance and to determine if menopause status modifies response to diabetes prevention interventions.
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The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health Service or other funding agencies. A complete list of centers, investigators, and staff participating in the Diabetes Prevention Program can be found in the Appendix. androgens are associated with glucose intolerance in both premenopausal and postmenopausal women. 2 Third, postmenopausal estrogen therapy reduces fasting plasma glucose (FPG) levels. 3 It is unknown if menopause per se is associated with higher glucose levels, particularly among women who are already glucose intolerant. Because diabetes is typically defined by glucose levels, the presence of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) is a strong risk factor for diabetes, and the menopausal state may not have any additional effect. Although several longitudinal studies have found no association between menopause and glucose, 4<6 these studies did not measure the associations between menopause and the key mediators of glucose tolerance, specifically insulin secretion and insulin resistance, or other biomarkers. Furthermore, these studies did not compare diabetes risk among the population of women with bilateral oophorectomy with those with natural menopause. Bilateral oophorectomy reduces testosterone levels, 7 and high testosterone is a risk factor for diabetes in women. 2 Finally, it is also unknown if diabetes prevention interventions are more effective in premenopausal compared with postmenopausal women.
If menopause status is a risk factor for diabetes among women who are already at high risk or modifies response to diabetes prevention interventions, this has implications for targeted diabetes prevention interventions. The Diabetes Prevention Program (DPP) was a randomized trial of diabetes prevention interventions among adults with IFG and IGT. Using the data from the DPP, we examined diabetes risk associated with menopause status, comparing women who were premenopausal with women who were postmenopausal at baseline. We also examined if menopause status modified the effect of DPP interventions on a number of metabolic variables, including adiposity, insulin metabolism, glucose, adiponectin, C-reactive protein (CRP), fibrinogen, and tissue plasminogen activator antigen (tPA). Finally, we examined whether the associations between natural menopause and diabetes risk differed from those of bilateral oophorectomy and diabetes risk before and after consideration of hormone therapy (HT).
METHODS
Characteristics of DPP participants have been reported. 8 Briefly, the DPP inclusion criteria included the following: age 25 years or older, an FPG of 5.3 to 6.9 mmol/L or 95 to 124 mg/dL (e6.9 mmol/L in the Native American centers) and a 2-hour plasma glucose of 7.8 to 11.1 mmol/L or 140 to 200 mg/dL after a 75-glucose load, and a body mass index of 24 kg/m 2 or higher (Q22 kg/m 2 for Asian Americans). Written informed consent was obtained from all participants before screening, consistent with the guidelines of each center's institutional review board.
Eligible participants recruited between 1996 and 1999 were randomly assigned to one of three interventions: 850 mg metformin twice daily, placebo twice daily, or intensive lifestyle. The goals of the lifestyle intervention were to achieve and maintain a weight reduction of at least 7% of the initial body weight through consumption of a low-calorie, low-fat diet and to engage in moderate physical activity for at least 150 minutes/week. 8 Diabetes was diagnosed on the basis of an annual oral glucose tolerance test (OGTT) or a semiannual FPG test. 9 The diagnosis required confirmation by a second test, usually within 6 weeks. At the time of randomization, all women completed a questionnaire about their menses, gynecologic history including surgeries, current oral contraceptive (OCP) use, and HT use. Menstrual bleeding pattern in the previous year was not assessed beyond baseline, nor was the type of HT or OCP ascertained. Participants were followed for an average of 3.2 years, updated from the 2.8 years reported previously. 8 For this analysis, we included female DPP participants aged 40 to 64 years at randomization. The cutoff of 40 years was chosen to exclude Bpremature[ or atypical menopause, typically defined as cessation of menses before the age of 40 years. 10 The cutoff of 65 years was chosen to exclude women who reported continued vaginal bleeding after the age of 65 years because this bleeding was less likely to occur due to menses and more likely to occur due to pathologic processes; thus, we chose an age range that would include women who could be premenopausal or postmenopausal. We excluded women who reported irregular menses in the past year, or who initiated HT while menstruating, or who reported menses up to the time of hysterectomy (n = 384).
Women reporting current, regular menstruation were classified as being premenopausal (n = 708). Women were classified as being postmenopausal at baseline if they reported that at least 1 year had elapsed since their last menstrual period (n = 529). Among postmenopausal women, women were classified as having surgical menopause if they reported bilateral oophorectomy (n = 201). Among women who reported not bleeding for at least 1 year, women were classified as being in natural menopause if they had a uterus and at least part of one ovary, or if they stopped menstruating at least a year before a hysterectomy and had at least part of one ovary (n = 328). Other self-reported variables included age, race/ ethnicity, family history of diabetes, smoking history, parity, history of gestational diabetes mellitus (GDM), and menopause status.
Glucose and insulin were measured as previously reported. 11 Briefly, women were instructed to consume a usual diet, and an OGTT was performed between 7 AM and 11 AM after an overnight fast. Blood was sampled from a vein before (fasting) and 30 minutes and 2 hours after a 75-g oral glucose load (Trutol 75; Custom Laboratories, Baltimore, MD). Plasma glucose was measured fasting, at 30 minutes, and at 2 hours, and plasma insulin was measured fasting and at 30 minutes. A-Cell function was assessed using the corrected insulin response (CIR) = (100 Â 30-min insulin)/(30-min glucose Â [30min glucose j 70 mg/dL]). 11 Insulin sensitivity was assessed using inverse fasting insulin levels. 11 Total circulating adiponectin was measured at baseline and 1 year after randomization using a latex particleYenhanced 858 Menopause, Vol. 18, No. 8, 2011 turbidimetric assay (Otsuka Pharmaceutical, Tokyo, Japan). The within-run and total coefficient of variation for this assay are 0.8% to 1.9% and 1.1% to 2.0%, respectively, and results are highly correlated with enzyme-linked immunosorbent assayYbased methods (r = 0.99). 12 Other analytes were measured at baseline and at 1 year postrandomization in a central laboratory as previously reported. 12 High-sensitivity CRP and fibrinogen levels in plasma were measured immunochemically using Dade-Behring reagent on the Behring Nephelometer autoanalyzer, which uses polystyrene particles coated with monoclonal antibodies specific to the ligand. The intra-assay and interassay coefficients of variation for CRP were 4% and 5%, respectively. The intra-assay and interassay coefficients of variation for fibrinogen were 3% and 5%, respectively. 13 tPA was measured in citrated plasma using an enzyme-linked immunosorbent assay (Asserachrom tPA; Diagnostica Stago), which measures the total tPA antigen. 14 Baseline characteristics were described using percentages for categorical variables and means (SD) for quantitative variables. Comparisons between premenopausal and postmenopausal women were made using the W 2 test of independence for categorical variables and the t test for quantitative variables. Cox proportional hazard models were used to assess the association between menopause status and diabetes risk after adjustment for age, race/ethnicity, family history of diabetes, history of GDM, waist circumference, insulin resistance (defined as 1/fasting insulin), and CIR. 11 Models were constructed for the entire sample, for premenopausal women and women in natural menopause only, for premenopausal women and women with bilateral oophorectomy, for premenopausal women and postmenopausal women not using HT currently, and for premenopausal women and postmenopausal women using HT currently.
To determine if baseline menopause status modified response to interventions, we used a normal errors longitudinal regression model 15 to compare age and baseline-adjusted weight, waist circumference, insulin resistance, CIR, 11 and glucose levels by menopause status. We also examined changes in biomarkers including adiponectin, CRP, fibrinogen, and tPA within study arm and found no differences by menopause status (results not shown), and we stratified by GDM status but found no differences by menopause status (results not shown). 
RESULTS
Baseline characteristics of women by menopause status and type of menopause are shown in Table 1 . Premenopausal women were younger than postmenopausal women, with a mean (SD) age of 45.7 (3.6) years at enrollment; based on previous longitudinal studies, 10 we would estimate that less than 10% of premenopausal women would have naturally transitioned to menopause over the 3-year period. Premenopausal women were also more likely to have a history of GDM and to have ever used OCPs; postmenopausal women were more likely to have ever used HT. Although premenopausal women were heavier and had greater waist circumference than women in natural menopause, premenopausal women had similar body habitus to women with bilateral oophorectomy. Compared with women in natural menopause, premenopausal women had lower fibrinogen, adiponectin, and greater tPA. Compared with women with bilateral oophorectomy, premenopausal women had lower CRP and lower adiponectin and tPA.
The unadjusted cumulative incidence of diabetes among premenopausal women was, in cases per 100 person-years, 11.8 in the placebo group, 6.6 in the metformin group, and 6.8 in the lifestyle group. Among postmenopausal women, the unadjusted cumulative incidence of diabetes was, in cases per 100 person-years, 11.5 in the placebo group, 8.9 in the metformin group, and 3.2 in the lifestyle group. Among women in natural postmenopause, the unadjusted cumulative incidence of diabetes was, in cases per 100 person-years, 10.5 in the placebo group, 5.0 in the metformin group, and 4.3 in the lifestyle group. Among women with bilateral oophorectomy, the unadjusted cumulative incidence of diabetes was, in cases per 100 person-years, 12.9 in the placebo group, 10.3 in the metformin group, and 1.1 in the lifestyle group.
The hazard ratio of diabetes by baseline menopause status before and after adjustment for demographic factors, waist circumference, and CIR and 1/fasting insulin is shown in Table 2 . When we examined premenopausal women and postmenopausal women in menopause (natural and bilateral oophorectomy), postmenopause status was not significantly associated with diabetes risk among women in any randomization arm after adjustment for age. This pattern persisted after further adjustment for other demographic factors including race/ethnicity, family history of diabetes, and history of GDM and after additional adjustment for waist circumference, insulin resistance, and CIR. When we compared premenopausal women to women in natural menopause ( Table 2) , postmenopausal women did not have a greater risk of diabetes overall. Although postmenopausal women in the lifestyle arm had a higher risk for diabetes after consideration of multiple risk factors, this risk was not statistically significant. When we compared premenopausal women to women with bilateral oophorectomy (Table 2), we found that postmenopausal women did not have a higher risk of diabetes in any treatment arm. In the lifestyle arm, women who had undergone bilateral oophorectomy had a significantly lower risk for diabetes; that is, women with bilateral oophorectomy seemed to have a greater benefit from lifestyle intervention as compared with women in premenopause and greater benefit from lifestyle intervention than metformin. This result persisted after adjustment for age, race/ethnicity, family history of diabetes, history of GDM, waist circumference, 1/fasting insulin, and CIR (Table 2) .
Next, we performed these analyses stratified by HT use as well as the type of menopause (Table 3 ). Natural menopause was not associated with greater diabetes risk overall among HT users or nonusers. Women in natural menopause who were not using HT had similar diabetes hazard compared with premenopausal women by treatment arm, and women in natural menopause who were using HT also had similar diabetes hazard compared with premenopausal women by treatment arm. Bilateral oophorectomy was also not associated with greater diabetes risk overall among HT users and nonusers within treatment arm. In the lifestyle arm, women who had undergone bilateral oophorectomy had a nonsignificantly lower risk for diabetes among HT nonusers. However, no HT users with bilateral oophorectomy developed diabetes within the lifestyle arm, and thus, we could not determine if bilateral oophorectomy modified response to lifestyle intervention, apart from HT.
To determine whether the impact of interventions on potential mediators was modified by overall menopause status, we compared the changes in weight, waist circumference, 1/ fasting insulin, CIR, FPG, and 2-hour glucose levels within study arm and found no significant differences by menopause status after adjustment for age (results not shown). Finally, we examined the changes in biomarkers including adiponectin, CRP, fibrinogen, and tPA within study arm and found no differences by menopause status (results not shown).
DISCUSSION
No previous longitudinal reports have examined the impact of menopause among women who are already at high risk for diabetes based on glucose levels. In this randomized 3-year trial of interventions for diabetes prevention among women with IFG and IGT, we found that natural menopause was not associated with an increased risk of diabetes. Overall, we found that bilateral oophorectomy was not associated with a de-creased risk of diabetes. Bilateral oophorectomy was associated with a decreased risk of diabetes among women randomized to lifestyle intervention, but we could not assess whether this effect was independent of HT.
At the beginning of these analyses, several factors suggested that menopause status may be associated with higher risk of diabetes in the general population of women: (1) postmenopause may be a relatively androgenic state compared with premenopause due to cessation of ovarian estrogen production and continuation of androgen production by the ovarian stroma 1 ; (2) polycystic ovary syndrome (PCOS) is associated with higher androgen levels, and women with PCOS have a greater risk of diabetes than women without PCOS 16 ; (3) higher levels of androgens are associated with glucose intolerance in premenopausal and postmenopausal women 2 ; and (4) HT is associated with lower FPG values. 3 However, the relationship between androgens and glucose has not been consistent. In one cross-sectional study of postmenopausal women (n = 29), greater endogenous androgens were actually associated with an improved insulin sensitivity. 17 Correction of hyperandrogenemia in women with PCOS has not been associated with a change in insulin sensitivity, suggesting that androgens per se may not change insulin sensitivity in that population, with the caveat being that findings in PCOS women may not extend to the general population of healthy women. 18 For women in natural menopause, there are three potential explanations why the DPP cohort showed no association between menopause status and diabetes risk. First, all women in the DPP were preselected for IGT at baseline, and Reference is premenopausal women; a hazard ratio greater than 1 indicates greater diabetes risk among postmenopausal women. HT, hormone therapy; GDM, gestational diabetes mellitus; CIR, corrected insulin response.
menopause may not be a significant risk factor for glucose deterioration among women who are already glucose intolerant. Second, postmenopause status may not increase diabetes risk. Third, although this analysis included more than 1000 women who were premenopausal and in natural menopause, our study may have been underpowered to detect a real, if modest, difference after consideration of age.
To our knowledge, no previous longitudinal reports have examined separately diabetes risk in women with bilateral oophorectomy. The Study of Women's Health Across the Nation (SWAN), which serially examined women as they progressed through menopause, included only premenopausal women and women in natural menopause. 4 In SWAN, the ageadjusted odds of developing metabolic syndrome (although not diabetes) in perimenopausal women were significantly higher than in postmenopausal women. 4 In a report by Soriguer et al, 5 no specification was made regarding surgical versus natural menopause, and no significant risk of diabetes was found in the postmenopausal population. Finally, in a report from Mishra et al, 6 no association between menopause status or type of menopause status was found to be associated with diabetes risk. In this article, surgical menopause was defined as hysterectomy with or without oophorectomy, so that women in Bsurgical menopause[ could have retained both ovaries, which may have led to overlapping hormone profiles between women in Bnatural[ versus Bsurgical[ menopause.
In our analysis, the decreased diabetes risk associated with bilateral oophorectomy among women enrolled in the lifestyle arm was initially masked by the slight (but nonsignificant) risk in natural menopause, and this may have occurred in the analysis of Soriguer et al and Mishra et al as well. In our analysis, among women randomized to the lifestyle arm, women with bilateral oophorectomy had a significantly lower risk of diabetes compared with premenopausal women. Among women randomized to the lifestyle arm, women in natural menopause had a risk of diabetes similar to that of premenopausal women. Women with bilateral oophorectomy used HT more often than did women in natural menopause (69% vs 39%, respectively) and tended to have slightly higher weight and greater insulin resistance than did women in natural menopause. Therefore, it is possible that the differences in diabetes hazard in the lifestyle arm in women with bilateral oophorectomy and women in natural menopause may have been mediated or confounded by HT use.
Women with bilateral oophorectomy represent a unique population because they have a sudden dramatic decrease in both their androgen and estrogen production. We did not see a significant differential association between natural menopause and diabetes in the DPP lifestyle group, even as we observed it in the bilateral oophorectomy group. Our findings underscore the potential importance of examining women with bilateral oophorectomy separately from women in natural menopause. Although explanations are speculative, the absolute declines in sex hormones and/or relative differences in the balance of these hormones after bilateral oophorectomy may have contributed to a greater benefit of lifestyle intervention among these women, or the more frequent HT use may have also contributed to this greater benefit. In the current report, associations between menopause and diabetes incidence were not altered after consideration of waist circumference in overall, or bilateral oophorectomy, or natural menopause cohorts. In the parent DPP study, lifestyle intervention was more effective in older age groups. 19 In our report, among women in natural menopause, the similar diabetes incidence after exclusion of HT users and among current HT users further supports the conclusion that HT may not significantly modify diabetes risk among women who are already glucose intolerant. We were unable to assess the impact of HT among women with bilateral oophorectomy in the lifestyle arm, because of the lack of diabetes cases in that arm. We did not ascertain the different types of HT, or intermittent use, common in many postmenopausal women and therefore cannot comment on the associations with diabetes risk between any specific hormone regimen or route of administration. However, at the time the DPP was initiated in 1996, more than 80% of HT use in the United States was oral conjugated equine estrogens (CEE) with or without medroxyprogesterone acetate (MPA). 20 The epidemiologic literature on HT and diabetes incidence is contradictory. Observational studies are confounded by the fact that women with diabetes are much less likely to be prescribed estrogen, 21 and few studies measured postchallenge glucose.
Among women without known diabetes, one prospective cohort study 22 and two randomized clinical trials 3, 23 suggested that oral CEE with continuous MPA decreased diabetes risk, but the diabetes diagnosis was based on self-report without postchallenge glucose, and both trials included women with an intact uterus. In contrast, the Postmenopausal Estrogen/ Progestin Interventions Study, the largest, longest randomized trial to include OGTT as outcome, showed that oral CEE with MPA decreased FPG but also increased 2-hour glucose; results were not reported separately by oophorectomy history. 24 Another large trial of unopposed estrogen in women who had a hysterectomy reported a nonsignificant reduced risk of diabetes based on fasting glucose 25 ; although approximately 40% of that cohort had undergone bilateral oophorectomy, results were not reported separately by oophorectomy history. Clinical trials of HT in women with known diabetes have been small and short, had divergent results, and were not able to determine impact among women with bilateral oophorectomy versus natural menopause. 26<28 This study is unique in its ability to assess a history of menopause and HT as risk factors for diabetes in women with IGT and in having repeated measures of fasting and postchallenge glycemia and diabetes diagnoses confirmed by a second glucose assay. However, we also note several limitations. Bilateral oophorectomy was self-reported. Menopause status was not queried after baseline; therefore, we could not assess the change in menopause status; some premenopausal women whose mean age was 46 years at baseline may have transitioned to postmenopause during the 3-year study period. In the SWAN study, more than 80% of women who enrolled at age 42 years were still menstruating at a 6-year follow-up. 10 Based on SWAN observations and the fact that premenopausal DPP women had a mean (SD) age of 45.7 (3.6) years at enrollment, we would estimate that less than 10% of premenopausal women would have transitioned to menopause over the 3-year period. The use of OCPs to manage perimenopausal symptoms could have affected premenopausal progression to diabetes, but OCP use was reported by only 6%. Taken together, these limitations may have biased our results to the null among women in natural menopause. We cannot exclude the possibility that natural menopause is associated with altered glucose tolerance among women who have normal glucose levels before treatment. We were unable to assess the effects of HT among women in surgical menopause in the lifestyle arm, because of the lack of diabetes cases in that arm. Finally, as in any observational study, there may have been residual confounding by factors such as age.
CONCLUSIONS
The present report has clinical and public health relevance, showing that natural menopause does not modify the impact of diabetes prevention interventions among women at high risk for diabetes. Although we did not find a significant association between natural menopause and diabetes risk, our study cannot completely rule out a more modest association. Bilateral oophorectomy may have different effects on response to lifestyle interventions than natural menopause, but the role of HT needs to be assessed.
